Twenty-six patients who had undergone recent surgery for differentiated thyroid cancer were
investigated using iodine-131 iodide (120 MBq). Uptake in the thyroid bed was measured at …

Aim We evaluated the efficacy of two doses of I-131 (2220 MBq versus 3700 MBq) after
thyroid hormone withdrawal for thyroid remnant ablation postoperatively in patients with …

Objective: Remnant ablation with radioactive iodine (I-131) is a successful form of treatment
that aims to destroy the remaining residual tissue and/or metastatic tissue after total …

Objectives Currently, little is known about the prognostic significance of achieving successful
ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study …

The main approach to differentiated thyroid cancer (DTC) therapy is still empiric, consisting
of the administration of fixed activities. Repeated treatments, however, may have a stunning …

Low‐risk (LR) differentiated thyroid cancer (DTC) patients should be ablated or not, albeit,
with small dose of radioiodine is highly controversial. We hypothesized that those LR DTC …

Objective To investigate predictors for successful ablation and disease-free status after high-
dose radioiodine therapy in patients with differentiated thyroid cancer. Methods We enrolled …

Background: The utility of radioiodine (RAI) scans prior to 131I ablation is controversial. The
objective of this study was to evaluate the utility of RAI scans prior to 131I ablation in patient …

Objective To determine the success of ablative treatment using fixed high doses of 131 I in
patients with thyroid cancer. Methods A retrospective study was conducted on 274 patients …

Purpose We speculated that radioiodine remnant ablation (RRA) could be performed less
frequently in differentiated thyroid cancer (DTC) patients, if the recommendations of the 2018 …